Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of adjunctive NBI-1065845 in major depressive disorder
2024-519423-24-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of osavampator in major depressive disorder (MDD), sponsored by Neurocrine Biosciences. Primary endpoint: Occurrence of adverse events. Planned start Oct 2025; status: authorised.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-519423-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519423-24-00.